Riskpilot← Back to searchSign inGet full accessCellMatrix AB
ABActiveOrg 5565630026Medicinaregatan 8 AManufacture of pharmaceutical preparations · NACE 2120Est. 19990 employees
Revenue 2024
SEK 0
EBITDA margin
—
+16% vs 2023
Equity ratio
50.5%
Financial strength
Net profit 2024
SEK 6K
+250% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -16K | +16% |
| Net profit | SEK 6K | +250% |
| Total assets | SEK 317K | -27% |
| Equity | SEK 160K | -37% |
| Employees | 0 | — |
Legal name
CellMatrix AB
Org number
5565630026
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
19 februari 1999
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall främja forskning och utveckling av medicinteknik och kirurgi, att kommersialisera de utvecklade produkterna samt att bedriva därmed förenlig verksamhet.
Address
Medicinaregatan 8 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 295 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 294 | −25 | −26 | −19 | −16 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 294 | −25 | −26 | −19 | −16 |
| Net financials | −160 | −80 | — | 3 | 4 |
| Profit before tax | 214 | −42 | −2 | −4 | 9 |
| Tax | −63 | −0 | −0 | −0 | −3 |
| Net profit | 151 | −42 | −2 | −4 | 6 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 567 | 1 173 | 648 | 432 | 317 |
| Equity | 2 002 | 960 | 458 | 254 | 160 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 344 | 15 | 15 | 15 | 15 |
| Total debt | 344 | 15 | 15 | 15 | 15 |
EBITDA margin
-1600000.0%
This company
15.8%
Market median
-10126682% vs market
20202024
Equity ratio
50.5%
This company
38.2%
Market median
+32% vs market
20202024
Return on equity
3.8%
This company
18.4%
Market median
-79% vs market
20202024
Net profit margin
600000.0%
This company
8.1%
Market median
+7407307% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.98×
This company
0.62×
Market median
+58% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PP | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CellMatrix AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pelle Per Lennart Bender | Audit | 0 companies |
| Kerstin Lillemor Peterson | Deputy Board Member | 0 companies |
| Lars Gustaf Birger Peterson | Chairman | 0 companies |
| Anders Harald Lindahl | Board of Directors | 0 companies |